Amy Abernethy, MD, PhD
ON DECEMBER 17, 2018, the U.S. Food and Drug Administration (FDA) announced that Amy Abernethy, MD, PhD, will replace Rachel Sherman, MD, MPH, as Principal Deputy Commissioner of Food and Drugs.
Dr. Abernethy most recently served as Chief Medical Officer, Chief Scientific Officer, and Senior Vice President, Oncology, at Flatiron Health. Before joining Flatiron Health, Dr. Abernethy was Professor of Medicine at Duke University School of Medicine and ran the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute.
Ellen V. Sigal, PhD
“[Dr. Abernethy] is truly an innovator,” commented Ellen V. Sigal, PhD, Chair and Founder of Friends of Cancer Research. “As a treating physician, not only does she know firsthand the importance and power of the impact the FDA has on patients every day, but she has shown in her many leadership capacities that to make true advances and save lives, you must always innovate with the patient at the forefront. This appointment, in many ways, is a natural progression from the pivotal work that Rachel Sherman has paved the way for since her return to the FDA in 2015.” ■
